By Elena Vardon
Celadon Pharmaceuticals is set to delist from London's AIM after its directors resigned.
The medical cannabis firm on Monday said that it will propose to move ahead with the cancellation of trading of its shares at a general meeting.
This follows a proposal put forward on Wednesday by Chief Executive James Short--who owns 39.5% of the company--to remove four non-executive directors and Chairman Alexander Anton. The board hadn't been supportive of Short's proposal to delist to reduce operational costs and access capital on easier and more attractive terms.
On Friday, directors Robert Barr, Elizabeth Shanahan, David Firth and Steven Hajioff resigned following talks, it said.
Anton is reviewing his position as chair and will resign from the board if the cancellation is approved by shareholders, Celadon added.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
March 24, 2025 03:41 ET (07:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。